Introduction {#sec1-1}
============

Individuals with osteoporosis, a skeletal disorder characterized by compromised bone strength, have an increased risk of fracture.^[@ref1]^ Low bone mineral density (BMD), including that seen in individuals with premature osteopenia and osteoporosis, is more common in persons who are infected with human immunodeficiency virus (HIV)^[@ref2]^ than in uninfected persons, and there is evidence showing that antiretroviral therapy (ART) could increase bone loss. Low BMD is more prevalent in HIV infected subjects, and antiretroviral therapy (ART) can increase bone loss;^[@ref3]^ this treatment is associated with a 2-6% decrease in BMD over the first 2 years, which is similar in magnitude to that observed during the first 2 years of menopause.^[@ref4]^ Chronic hepatitis C co-infection are associated with higher incidences of fractures whereas older age, female gender, an acquired immune deficiency syndrome (AIDS) diagnosis, baseline plasma HIV RNA viral load, and low body mass index (BMI) are related with low BMD.^[@ref5]^

A number of studies have described accelerated bone loss and increased rates of osteopenia and osteoporosis among HIV-infected individuals, as compared to those in a general population.^[@ref6]^ Previous studies have suggested that antiretroviral drugs, which are commonly used to treat patients with HIV have a negative impact on bone health. Nucleoside reverse transcriptase inhibitors (NRTIs) as tenofovir (TDF) is associated with a greater decline in BMD as compared to that seen with abacavir (ABC).^[@ref7]^ Exposure to protease inhibitors (PIs) decreases BMD, and it has recently been suggested that atazanavir is associated with an increased risk of osteoporosis, as compared to that with efavirenz.^[@ref8]^ There are reports of bone disorders such as avascular necrosis of the hip and compression fracture of the lumbar spine in HIV-infected patients receiving PIs.^[@ref9]^ Lower lumbar and thoracic spine BMD have been identified in up to 30% of HIV-infected individuals treated with PIs.^[@ref10]^ The prevalence of bone weakness (and/or fractures) in these patients needs regular screening. Dual energy X-ray absorptiometry (DEXA) is used to evaluate BMD in patients with HIV;^[@ref11]^ however, low and middle-income countries often do not have access to it. We hypothesized that a lateral spine X-ray could aid in the identification of a proportion of patients with vertebral fractures.

The aim of this study was to determine the prevalence of and factors associated with, vertebral fractures (since they are fragility fractures more easily measurable) in HIV infected patients in a tertiary level infectious disease care hospital in Mexico.

Materials and Methods {#sec1-2}
=====================

Design {#sec2-1}
------

We conducted a cross-sectional study from August 2015 to February 2016 at the Hospital de Infectología, *La Raza* National Medical Center, a tertiary-level hospital for infectious disease in Mexico City, Mexico.

Patients {#sec2-2}
--------

Persons who came to the outpatient HIV clinic and were 40 years old, due to the fact that from that age the risk of fracture starts, and being treated with ART were invited to participate.

The study was approved by the Institutional Review Board number 3502 and protocol number is R-2016-3502-2. All participants provided written informed consent before completing a questionnaire that assessed the epidemiological, immunological, virological and clinical risk factors for osteoporosis. Except for the patients who had previously been prescribed steroids, we excluded any patients who were being treated with anti-osteoporotic drugs and/or with drugs that cause osteoporosis and fractures.

Questionnaire {#sec2-3}
-------------

Patients filled a questionnaire on personal characteristics (age, sex, and duration of HIV infection), body composition (height, weight and BMI), risk factors for low BMD (history of fractures, smoking status, corticosteroid use and alcohol consumption), hepatitis B and C coinfection, diabetes mellitus, chronic renal failure, CD4+ cell count, nadir of CD4+ cell counts, HIV-1 RNA viral load, AIDS diagnosis, and type and duration of ART.

Measurements {#sec2-4}
------------

Each patient´s spine was imaged by lateral spine X-ray. Vertebral deformities were identified using a semi-quantitative morphometric analysis of centrally digitalized images. Anterior, middle and posterior vertebral heights were measured, and height ratios were calculated. For each vertebral body fractures were defined as mild, moderate and severe based on height ratio decreases of 20-25% (grade 1), 26-40% (grade 2) and \>40% (grade 3), respectively; ^[@ref12]^ the height relationships were calculated with a rule to evaluate the compression in millimeters. For each patient, the *spine deformity index* (SDI) was calculated by summing the grades of vertebral deformities according to the semiquantitative method described by Genant *et al.*^[@ref12]^ An SDI \>1 was indicative of vertebral fracture according to its definition (reduction in vertebral height of 4 mm or 20-25%).

Statistical analysis {#sec2-5}
--------------------

Analyses were performed using SPSS v.20 and EPIDAT v 3.8. The Kolmogorov- Smirnov test was used to determine the sampling distribution. Descriptive results were summarized using median and interquartile ranges (IQRs). The chisquared test was used to compare categorical variables. Analyses of continuous variables were performed using the Mann Whitney test. P\<0.05 was considered to be statistically significant.

Results {#sec1-3}
=======

A total of 104 patients were included in the study, 87% of whom were men. The median age was 49 years (IQR 42-52). Among the patients that were studied, the most common CDC stages were B2, a2, A1 and A3, accounting for 39%, 36%, 8% and 8%, respectively. Overall, 47 patients (45%) were being treated with PIs or had taken PIs in the past and 100 (96%) were taking TDF or had previously taken TDF. At the time of the study, 83 (80%) had an undetectable HIV-1 RNA viral load (HIV-1 RNA \<20 copies/mL). Thirty-two (31%) patients had previously had a fracture, and 4 (4%) were co-infected with HCV. In addition, 57 (55%) patients had a history of corticosteroid treatment, with prednisone being the most prescribed corticosteroid in 47 (45% patients). Regarding family fractures, 19 (18%) patients were positive for this antecedent, and 7 (7%) used anticonvulsants in the past.

We found that 27 (25%, 95% CI 17-34%) patients in our study had vertebral fractures. Out of these patients, 17 (62%) had mild fractures, 8 (29%) had moderate fractures, and 2 (7%) had severe fractures. We assessed the following features for associations with an increased risk of fracture: female gender, HCV co-infection, and previous corticosteroid use showed a trend toward association with an increased risk of vertebral fracture, but this association was not statistically significant. In our cohort, none of the other factors assessed were significantly associated with spine fracture ([Table 1](#table001){ref-type="table"}).

Discussion and Conclusions {#sec1-4}
==========================

The combination of two factors (survival and prolonged exposure to ART) has led to the development of so-called non- AIDS events, which have gained significant relevance in the morbidity and mortality of the HIV-positive population.

The high prevalence of osteopenia and osteoporosis observed in the HIV-infected population and the increased risk of fragility fractures have prompted clinicians to establish screening programs aimed at identifying patients who are eligible for preventive therapy.

In our study, we found that the prevalence of vertebral fractures in patients who were \>40 years old and infected with HIV was high; however, we were not able to identify risk factors associated with the incidence of fractures.

Many patients in our study were being treated with PIs at the time of the study or had previously been treated with PIs and were currently being treated with TDF. Several studies have suggested an association between BMD reduction and treatment with PIs or with TDF. Arnstern *et al.* reported that neither ART nor PI use is associated with decreased BMD.^[@ref13]^ In contrast, in the TROOP study, switching from tenofovir to raltegravir in virologically suppressed, HIV-infected adults with low BMD who were stable on an PI-containing regimen resulted in statistically significant improvements in both hip and spine BMD at 48 weeks and significant reductions in plasma \[BTMs (bone turnover markers)\] by 24 weeks and a TDF switch to raltegravir yielded hip and spine BMD increases of 2.5 and 3.0%, respectively.^[@ref14]^ In the ASSERT study, a greater BTM increase was found with TDF plus emtricitabine compared with ABC plus lamivudine.^[@ref15]^ Bedimo *et al.* found that concomitant exposure to TDF and PIs was associated with an increased risk of osteoporotic fractures, as compared to patients exposed to TDF without PIs or to PIs without TDF and reported more minimal trauma fractures with TDF-based ART (relative risk 1.12 per year of TDF exposure). ^[@ref14]^

ART causes approximately 3-6% loss of BMD in the first year of ART, similar to the amount of BMD loss with menopause, this loss occurs on a background of lower BMD in the HIV-infected population, particularly with longer duration of HIV infection.^[@ref14]^

Patient histories revealed that some of the subjects were co-infected with HCV and had a history of treatment with corticosteroids. Corticosteroids have wellestablished adverse effects on the bone with a clear relationship seen between corticosteroid use and fracture in the general population; in HIV-infected individuals, corticosteroid use also has been shown to be associated with fracture risk.^[@ref16]^

The pathogenesis for an increased risk of osteoporosis associated with HIV is likely to be multifactorial and is not completely understood. Individuals who are infected with HIV have a high prevalence of traditional risk factors for osteoporosis including low BMD, poor nutrition, frequent use of glucocorticoids, smoking, vitamin D deficiency and co-infection with HCV.^[@ref17]^

Studies comparing fragility fractures in HIV-infected and uninfected men have been inconclusive. Collin et al*.* reported that the incidence of the first fracture was 3.3/1000 patient-years (95% CI 2.0, 4.6).^[@ref18]^ Arnstern *et al*. explored associations of HIV infection with BMD and incident fractures in HIVinfected and at-risk men aged 49 years or older.^[@ref11]^ Triant *et al.* reported a higher prevalence of wrist, hip and vertebral fractures among HIV-infected men than among uninfected men (3.08/100 persons *versus* 1.83/100 persons; P\<0.0001).^[@ref19]^ Borderi *et al.* performed lateral spine X-rays to assess the prevalence of subclinical vertebral fractures in 202 HIV-infected patients and reported a prevalence of 23.3% for vertebral fractures in these subjects,^[@ref20]^ which was similar to the findings of our study.

In a population-based nationwide cohort study using Danish registries, Hansen *et al*. reported that HIV-infected patients had a higher risk of fractures than compared with the population controls.^[@ref21]^ Among HIV-infected patients, an increased risk was observed for a low-energy fracture but not for a high-energy fracture, and the increased risk of a low-energy fracture was only observed in ART-exposed patients.^[@ref19]^ Fractures were reported in 15% of patients. However, that study focused on a young population. In our study, we only included vertebral fractures, that were low-energy fractures.

Risk of fragility fracture should be assessed primarily using the Fracture Risk Assessment Tool (FRAX), without dualenergy X-ray absorptiometry (DXA), in all HIV-infected men aged 40-49 years and HIV-infected premenopausal women aged ≥40 years.^[@ref22]^

Although there are numerous publications linking HIV infection to bone mineral decline, the World Health Organization (WHO), has not included HIV in the fracture elevation *score* (FRAX) to date.^[@ref22]^

Our study has some limitations, including the sample size and the absence of a control group; moreover there is heterogeneity of the population with regard to time, age, histories of the use of different antiretroviral and the variability of the treatment. In addition, we were not able to identify risk factors associated with vertebral fractures. We only considered vertebral fractures; although these fractures were once classified as fragility fractures, this classification was not mandated.

Finally, in some low and middleincome countries like Mexico that do not have access to a DEXA scan, the evaluation and treatment of bone disease is very difficult. In addition, this problem is complicated by reduced access to tests for bone markers. Thus, the radiological assessment of vertebral fractures could be an option for the evaluation of bone disease.

The authors wish to thank all of the centers and investigators who participated in this study.

###### 

Characteristics associated with an increased risk of fractures among patients in our study.

  Characteristics                         Odds ratio (95% CI)   P value
  --------------------------------------- --------------------- ---------
  Female gender                           0.50 (0.10-2.45)      0.39
  HCV co-infection                        3.1 (0.42-23.7)       0.23
  Previous corticosteroids use            0.51 (0.20-1.25)      0.13
  AIDS                                    0.53 (0.21-1.34)      0.18
  HIV-1 RNA viral load \>100,000 cop/mL   1.64 (0.29-9.12)      0.56
  Current or previous PIs use             0.85 (0.34-2.09)      0.73
  Current or previous TDF use             1.82 (0.54-3.2)       0.44

PIs, protease inhibitors; TDF, tenofovir.
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